Article

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced Melanoma

2022-08-01

Abstract excerpt

<title>Abstract</title> <p><bold>Background:</bold> Immune checkpoint inhibitors (ICIs) and targeted treatments have improved the health outcomes of patients with advanced melanoma. However, due to the high cost of novel therapies, it is crucial to evaluate their value by considering both effectiveness and cost.OBJECTIVE To compare the cost-effectiveness of these novel agents (atezolizumab-vemurafenib-cobimetinib...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 91274e93-7d4a-511d-89a9-04e2fc6441c0
DOI: 10.21203/rs.3.rs-1773968/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced MelanomaDOI 10.21203/rs.3.rs-1773968/v1Read

Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.Semantic proximity Read

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.Semantic proximity Read

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.Semantic proximity Read

Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.Semantic proximity Read

Analysis of Cost-Effectiveness of Trametinib Plus Dabrafenib as First-Line Therapy for Metastatic BRAF V600-Mutated Melanoma in ChinaSemantic proximity Read

Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.Semantic proximity Read

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.Semantic proximity Read

Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.Semantic proximity Read

Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF -Mutant Advanced MelanomaSemantic proximity Read

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.Semantic proximity Read

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read

Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.Semantic proximity Read